Trial · NCT02675465
Adverse events2,696
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 2,696
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Fall | Injury, poisoning and procedural complications | Cohort 1: ATB200 5 mg | 1 | 11 | 1 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 1: ATB 200 10 mg | 1 | 11 | 1 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 1: ATB200 20 mg | 0 | 11 | 0 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 1: ATB200 20 mg + 130/260 mg Miglustat | 2 | 11 | 2 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 1 ATB200 20 mg/kg + Miglustat 260 mg | 6 | 11 | 36 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 2 ATB200 20 mg/kg + Miglustat 260 mg | 2 | 6 | 4 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 3 ATB200 20 mg/kg + Miglustat 260 mg | 6 | 6 | 43 |
| other | Fall | Injury, poisoning and procedural complications | Cohort 4 ATB200 20 mg/kg + Miglustat 260 mg | 4 | 6 | 27 |
| other | Nasopharyngitis | Infections and infestations | Cohort 1: ATB200 5 mg | 0 | 11 | 0 |
| other | Nasopharyngitis | Infections and infestations | Cohort 1: ATB 200 10 mg | 1 | 11 | 1 |
| other | Nasopharyngitis | Infections and infestations | Cohort 1: ATB200 20 mg | 0 | 11 | 0 |
| other | Nasopharyngitis | Infections and infestations | Cohort 1: ATB200 20 mg + 130/260 mg Miglustat | 2 | 11 | 2 |
| other | Nasopharyngitis | Infections and infestations | Cohort 1 ATB200 20 mg/kg + Miglustat 260 mg | 9 | 11 | 19 |
| other | Nasopharyngitis | Infections and infestations | Cohort 2 ATB200 20 mg/kg + Miglustat 260 mg | 3 | 6 | 4 |
| other | Nasopharyngitis | Infections and infestations | Cohort 3 ATB200 20 mg/kg + Miglustat 260 mg | 4 | 6 | 5 |
| other | Nasopharyngitis | Infections and infestations | Cohort 4 ATB200 20 mg/kg + Miglustat 260 mg | 2 | 6 | 3 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Cohort 1: ATB200 5 mg | 0 | 11 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Cohort 1: ATB 200 10 mg | 0 | 11 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Cohort 1: ATB200 20 mg | 0 | 11 | 0 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Cohort 1: ATB200 20 mg + 130/260 mg Miglustat | 0 | 11 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02675465/events